Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.30), $0.58 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $30.34 million versus the consensus estimate of $59.28 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.